Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore! Learn More →

← Back to all trials

Recruiting NCT07241390

A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)

Conditions: Atherosclerosis Cardiovascular Disease, Chronic Kidney Disease

Sex: All

Ages: 50 Years – N/A

Healthy volunteers: No

Phase: PHASE3

Enrollment: 7140

Sponsor: Eli Lilly and Company

Location: Instituto de Investigaciones Clínicas Bahia Blanca Bahía Blanca

Summary

The purpose of this study is to measure cardiovascular outcomes with orforglipron compared with placebo in participants with atherosclerotic cardiovascular disease (ASCVD) and/or chronic kidney disease (CKD). Participation in the study will last about 5 years.

Eligibility Criteria

Inclusion Criteria: * Have established ASCVD and/or CKD Exclusion Criteria: * Have type 1 diabetes * Have had a major heart condition within 60 days prior to screening * Have New York Heart Association Functional Classification Class IV heart failure

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT07241390). StuddyBuddy aggregates publicly available trial information.